Introduction {#s1}
============

Sickle cell disease is an autosomal recessive haemolytic anaemia due to multiple genotypic mutations of adult haemoglobin. This haemoglobinopathy precipitates a complex metabolic cascade that causes erythrocytes under local hypoxia to polymerise and aggregate, leading to recurrent vaso-occlusive crises and decreased erythrocyte lifespan.[@R1] Sickle cell retinopathy (SCR), one of the ocular manifestations of sickle cell disease, is characterised by chronic retinal vascular ischaemia and occlusion due to the clogging of rigid sickle-shaped erythrocytes in the capillaries. Currently, intravenous fluorescein angiography (IV-FA) is the gold standard for evaluation of retinal vasculature and clinical staging in SCR. The advent of ultrawide IV-FA, in particular, has enabled capture of both the macula and peripheral retina up to 200° in a single image.[@R2] While the peripheral vasculature is especially susceptible to sickle cell disease, recent studies have demonstrated that macular involvement is also common.[@R4] IV-FA displays only the superficial macular capillaries with limited ability to provide quantitative information.[@R11] Optical coherence tomography angiography (OCT-A), which uses the contrast of erythrocyte motion to distinguish blood flow from the static signal of the background retinal tissue, offers additional information on tissue perfusion.[@R12] Compared with IV-FA, OCT-A features higher resolution with the capability of precise quantification of capillary abnormalities at the macula and may be a more sensitive imaging method for early detection and monitoring of SCR.

Sickle cell maculopathy develops from retinal ischaemia due to occlusion of the macular capillary networks, resulting in perifoveal capillary loss, alteration of foveal avascular zone (FAZ) morphology, formation of parafoveal microaneurysms and vascular loops, and nerve fibre layer thinning.[@R13] These macular abnormalities have been strongly associated with peripheral neovascularisation in patients with advanced SCR.[@R15] Prior OCT and OCT-A studies of SCR have reported that vascular abnormalities and retinal thinning are predominately located in the region temporal to the fovea.[@R5] However, these studies have been predominantly qualitative, and there remains limited quantitative evidence supporting the initial observations of regional susceptibility for SCR insult. In this study, we compared FAZ morphology in patients with SCR and controls using OCT-A. We also investigated any potential spatial propensity for parafoveal capillary dropout in patients with SCR, using a customised parafoveal capillary density method and mapping approach that provides both qualitative and quantitative assessments.

Materials and methods {#s2}
=====================

Subjects {#s2-1}
--------

This retrospective, cross-sectional study was conducted at the Johns Hopkins Wilmer Eye Institute with data analysis performed at the New York Eye and Ear Infirmary of Mount Sinai. The research study adhered to the tenets of the Declaration of Helsinki and was approved by the Johns Hopkins University School of Medicine Institutional Review Board. Diagnoses of patients with sickle cell of any genotype were determined through a comprehensive chart review and diagnostic wide-field IV-FA imaging conducted from September 2016 through May 2018 at the Johns Hopkins Wilmer Eye Institute. All patients with SCR underwent a complete ophthalmic examination by ophthalmologists, including ETDRS visual acuity testing, slit lamp biomicroscopy, dilated fundus examination, OCT and OCT-A imaging. SCR stage was graded according to Goldberg classification for each eye: stage I---peripheral arteriolar occlusions; stage II---peripheral arteriolar-venular anastomoses; stage III---preretinal neovascular; stage IV---vitreous haemorrhage; stage V---retinal detachment.[@R16] For patients in whom both eyes met inclusion criteria, a single eye was selected at random for inclusion in the study. Exclusion criteria for patients with sickle cell disease included cataract, vitreous haemorrhage, macular oedema, nystagmus, or a history of other retinal vascular disease such as hypertension, diabetes or retinal vessel occlusion. Selected patients with sickle cell disease were then placed one of two groups according to SCR stage: group 1 was non-proliferative SCR (NP-SCR) with stage II or less and group 2 was proliferative SCR (P-SCR) with stage III or above. Age and race-matched healthy controls were also enrolled. Exclusion criteria for healthy controls were the same. However, controls were also required to have a best corrected visual acuity of 20/20 or better and no prior ocular pathology or surgery.

OCT-A image acquisition {#s2-2}
-----------------------

OCT-A images were obtained with a commercial spectral-domain OCT system (Avanti RTVue-XR; Optovue, Fremont, CA, USA), with a scan rate of 70 000 A-scans per second, scan beam wavelength centred at 840 nm and a bandwidth of 45 nm. A single 3×3 mm scan, centred at the fovea, was acquired from each study participant. Following image acquisition, OCT-A images were generated by the Optovue AngioVue software (Angioanalytics, V.2018.0.0.16) which employs the split-spectrum amplitude-decorrelation angiography algorithm.[@R12] A 3×3 mm full vascular slab was designated for image processing and analysis, which included both large blood vessels and capillaries located between the inner limiting membrane and 70 µm below the posterior boundary of the inner plexiform layer ([figure 1](#F1){ref-type="fig"}A). Individual axial lengths were not measured at the time of imaging. A default axial length of 23.95 mm was used to derive the scan dimensions in millimetres.[@R17]

![Demonstration of optical coherence tomography angiography (OCT-A) image processing procedure in a patient with non-proliferative sickle cell retinopathy (NP-SCR). (A) Contrast-stretched full vascular slab OCT-A. (B) Manual segmentation of foveal avascular zone (FAZ). (C) Full vascular slab OCT-A after the removal of non-capillary blood vessels. (D) Parafoveal capillary segmentation highlighted in cyan. (E) Parafoveal capillary density map with non-capillary blood vessels indicated in white due to the exclusion from density computation. (F) Corresponding deviation map. Areas with parafoveal capillary density below 5% and 1% of the normal distribution are indicated in yellow and red, respectively. The temporal aspect of the parafovea is to the left in all images.](bjophthalmol-2019-314567f01){#F1}

OCT-A image processing and data analysis {#s2-3}
----------------------------------------

All image processing and data analysis were performed in the Einhorn Clinical Research Center at the New York Eye and Ear Infirmary of Mount Sinai. The first step involved manual delineation of the FAZ border on the full vascular slab OCT-A image using Adobe Photoshop (Adobe Systems, San Jose, CA, USA).[@R18] An FAZ mask was created based on the FAZ border delineation ([figure 1](#F1){ref-type="fig"}B). FAZ area, perimeter and acircularity index were then measured on the FAZ masks using MATLAB (The MathWorks, Natick, MA).[@R18]

On each greyscale full vascular slab OCT-A image, parafoveal capillary area was extracted after the removal of non-capillary blood vessels using global and local thresholding as described previously ([figure 1](#F1){ref-type="fig"}C, D).[@R19] This resultant OCT-A image contains only parafoveal capillaries for the generation of parafoveal capillary density map ([figure 1](#F1){ref-type="fig"}E). Parafoveal capillary density was then measured for five regions of interest (ROI) including the entire OCT-A image and four equiangular quadrants (temporal, nasal, superior and inferior) with the centre defined as the centroid on the FAZ mask.

For quantitative assessment, parafoveal capillary density (%) for each ROI was computed as described below:

$$\begin{matrix}
{Parafovealcapillarydensity,\%} \\
{= \frac{ParafovealcapillaryareameasuredatROI}{ROIarea - non - capillarybloodvesselarea - FAZarea} \times 100\%} \\
\end{matrix}$$

In both the control and SCR groups, individual density values on the parafoveal capillary density maps were compared against a previously established age and eccentricity-matched normative database (n=261, mean age 37 years; age range 5--87 years).[@R21] Individual parafoveal capillary density deviation maps highlighting the regions with capillary density at the extreme lower end of the normative curve were then generated for each control and patient with SCR ([figure 1](#F1){ref-type="fig"}F). On the deviation map, yellow and red colours indicate regions with parafoveal capillary density below 5% and 1% of the normal distribution, respectively. Per cent yellow and red areas were then computed for the same five ROIs as described in the parafoveal capillary density analysis.

For quantitative assessment, per cent yellow area and per cent red area (%) for each ROI were computed as described below:

$$\begin{matrix}
{Percentyelloworredarea,\%} \\
{= \frac{YelloworredareameasuredatROI}{ROIarea - non - capillarybloodvesselarea - FAZarea}} \\
\end{matrix} \times 100\%$$

Statistical analysis {#s2-4}
--------------------

All statistical analyses were performed using SPSS V.24.0 (IBM). To avoid interocular correlation, only one randomly selected eye from each participant was included for image processing and data analysis. Age, FAZ metrics, parafoveal capillary density measurements and per cent area deviated from normal distribution were all tested for normality in each study group using a Kolmogorov-Smirnov test. Since not all groups met the requirement for normality, comparison between groups was performed using the non-parametric Kruskal-Wallis and post hoc tests with the Bonferroni correction for multiple comparisons. Horizontal and vertical asymmetries in parafoveal capillary density measurements (temporal vs nasal quadrants and superior vs inferior quadrants) were compared using Wilcoxon signed-rank test in each group. Horizontal and vertical asymmetry analyses were similarly performed for per cent yellow area and per cent red area measured on the deviation map. Area under the receiver operating characteristic (AUROC) curve with 95% confidence interval (CI) was used to assess the diagnostic ability of FAZ metrics, parafoveal capillary density measurements and per cent area deviated from normal distribution to differentiate between eyes without SCR (control) and with any SCR (NP-SCR or P-SCR). A reference standard was provided by a retina specialist with full medical training to the fellowship level. SCR staging based on the Goldberg classification system was carried out by the reference standard.

Results {#s3}
=======

A total of 52 patients with sickle cell (33 NP-SCR and 19 P-SCR) and 20 age and race-matched controls from the Johns Hopkins Wilmer Eye Institute were included in this study. There was no significant difference in age (p=0.08, Kruskal-Wallis test) among the three study groups. The median age and range for the control, NP-SCR and P-SCR groups were 33 years (range: 22--55), 29 years (range: 19--70) and 39 years (range: 24--57), respectively. Participant characteristics are shown in [table 1](#T1){ref-type="table"}.

###### 

Participant characteristics

  Characteristics                               Results
  --------------------------------------------- -----------------------------------
  Participants, n                               72
  Race                                          African-American
  Eyes included for analysis                    72 (one eye per each participant)
  Median age and range (years)                  32.5; range 19--70
  Female, n (%)                                 46 (63.9)
  Right eye included, n (%)                     42 (58)
  Controls, n                                   20
  Patients with sickle cell disease, n          52
   Stratified by proliferative disease, n (%)    
   Non-proliferative (stage 2 or below)         33 (63.5)
   Proliferative (stage 3 or above)             19 (36.5)
   Stratified by sickle genotype, n (%)          
   Haemoglobin SS                               35 (67.3)
   Haemoglobin SC                               10 (19.2)
   Beta-thalassemia                             7 (13.5)

FAZ metrics {#s3-1}
-----------

Boxplots of the FAZ metrics are shown in [figure 2](#F2){ref-type="fig"}. There was no statistically significant difference between groups in FAZ area (p=0.606, Kruskal-Wallis test). However, FAZ perimeter was significantly greater in the P-SCR group when compared with the control group (p=0.045). FAZ acircularity index was significantly greater in the NP-SCR and P-SCR groups when compared with the control group with p=0.002 and p\<0.001, respectively (Kruskal-Wallis tests).

![Boxplots of foveal avascular zone (FAZ) metrics in different study groups. (A) FAZ area. (B) FAZ perimeter. (C) FAZ acircularity index. Significant p values for the post hoc pairwise comparisons after non-parametric Kruskal-Wallis tests are shown; all other comparisons were not significant (p\>0.05). NP-SCR, non-proliferative sickle cell retinopathy; P-SCR, proliferative sickle cell retinopathy.](bjophthalmol-2019-314567f02){#F2}

Parafoveal capillary density {#s3-2}
----------------------------

There were significant differences in total and quadrant parafoveal capillary densities among study groups. Parafoveal capillary density measured in the entire image was lowest in the P-SCR group (36.43%±3.46%), followed by the NP-SCR group (37.19%±4.00%) and the control group (41.45%±1.95%) ([table 2](#T2){ref-type="table"}). Boxplots of total and quadrant parafoveal capillary densities for each group are shown in [figure 3](#F3){ref-type="fig"}. Post hoc pairwise comparisons after non-parametric Kruskal-Wallis tests showed that parafoveal capillary densities measured in the entire image and four quadrants were significantly lower in the NP-SCR and P-SCR groups compared with the control group ([table 2](#T2){ref-type="table"} and [figure 3](#F3){ref-type="fig"}). No statistical significant difference between the NP-SCR and P-SCR was observed in all tested ROIs.

![Boxplots of parafoveal capillary density in different study groups. (A) Total parafoveal capillary density measured in the entire image excluding the foveal avascular zone (FAZ) area. (B) Temporal quadrant. (C) Nasal quadrant. (D) Superior quadrant. (E) Inferior quadrant. Significant p values for the post hoc pairwise comparisons after non-parametric Kruskal-Wallis tests are shown; all other comparisons were not significant (p\>0.05). NP-SCR, non-proliferative sickle cell retinopathy; P-SCR, proliferative sickle cell retinopathy.](bjophthalmol-2019-314567f03){#F3}

###### 

Non-parametric Kruskal-Wallis tests and post hoc pairwise comparisons for parafoveal capillary density and per cent area deviated from normal distribution measurements in three study groups

  Region of interest                 Mean±SD%     Kruskal-Wallis tests   Post-hoc pairwise comparisons                                          
  ---------------------------------- ------------ ---------------------- ------------------------------- ------------ ------------ ------------ ---------
  **Parafoveal capillary density**                                                                                                              
  Entire image                       41.45±1.95   37.19±4.00             36.43±3.46                      P\<0.001\*   P\<0.001\*   P\<0.001\*   P=0.980
  Temporal                           41.53±2.03   36.28±5.58             34.92±5.86                      P\<0.001\*   P\<0.001\*   P\<0.001\*   P=1.000
  Nasal                              41.79±2.13   37.81±3.65             37.65±2.84                      P\<0.001\*   P\<0.001\*   P\<0.001\*   P=1.000
  Superior                           41.38±2.18   36.98±4.43             35.95±3.93                      P\<0.001\*   P\<0.001\*   P\<0.001\*   P=1.000
  Inferior                           41.15±2.16   37.46±4.32             36.97±3.22                      P\<0.001\*   P\<0.001\*   P\<0.001\*   P=1.000
  **Per cent yellow area**                                                                                                                      
  Entire image                       4.59±3.75    15.94±14.90            18.00±11.72                     P\<0.001\*   P\<0.001\*   P\<0.001\*   P=0.833
  Temporal                           4.31±4.58    19.94±22.71            24.07±20.18                     P\<0.001\*   P\<0.001\*   P\<0.001\*   P=0.689
  Nasal                              3.75±2.96    13.49±12.40            13.44±10.60                     P\<0.001\*   P\<0.001\*   P\<0.001\*   P=1.000
  Superior                           4.71±4.61    16.56±16.08            20.76±14.37                     P\<0.001\*   P\<0.001\*   P\<0.001\*   P=0.614
  Inferior                           5.59±4.31    14.99±16.13            15.12±11.74                     P=0.008\*    P=0.023\*    P=0.017\*    P=1.000
  **Per cent red area**                                                                                                                         
  Entire image                       0.76±0.92    5.96±9.65              6.92±6.62                       P\<0.001\*   P=0.001\*    P\<0.001\*   P=0.346
  Temporal                           0.60±0.91    9.41±17.39             12.65±15.51                     P\<0.001\*   P=0.002\*    P\<0.001\*   P=0.568
  Nasal                              0.51±0.95    4.05±5.97              3.91±4.75                       P\<0.001\*   P\<0.001\*   P\<0.001\*   P=1.000
  Superior                           0.86±1.25    6.15±10.69             8.43±9.85                       P\<0.001\*   P=0.004\*    P\<0.001\*   P=0.178
  Inferior                           0.99±1.27    5.47±12.44             4.44±5.38                       P=0.011\*    P=0.035\*    P=0.017\*    P=1.000

\*P\<0.05.

NP-SCR, non-proliferative sickle cell retinopathy; P-SCR, proliferative sickle cell retinopathy.

In horizontal asymmetry analysis, the largest absolute parafoveal capillary density difference was found in the P-SCR group (3.33%±3.23%), followed by the NP-SCR group (2.60%±3.59%) and the control group (1.27%±1.13%). The same trend was also found in vertical asymmetry analysis with the largest absolute parafoveal capillary density difference found in the P-SCR group (2.97%±2.22%), followed by the NP-SCR group (1.95%±2.21%) and the control group (0.95%±0.71%). However, only the P-SCR group showed significantly horizontal asymmetry where parafoveal capillary density in the temporal quadrant was lower than that of the nasal quadrant (p=0.007, Wilcoxon signed-rank test) ([figure 4A, B](#F4){ref-type="fig"}).

![Boxplots show horizontal and vertical asymmetries of parafoveal capillary density (A, B), per cent yellow area (C, D) and per cent red area (E, F) measured at opposite quadrants in different study groups. (Left column) Temporal versus nasal quadrants. (Right column) Superior versus inferior quadrants. Only the temporal quadrant showed significantly lower parafoveal capillary density compared with the nasal quadrant in the proliferative sickle cell retinopathy (P-SCR) group. Temporal quadrant showed significantly higher per cent yellow area compared with the nasal quadrant in both non-proliferative sickle cell retinopathy (NP-SCR) and P-SCR groups. Significant p values for Wilcoxon signed-rank test are shown; all other comparisons were not significant (p\>0.05).](bjophthalmol-2019-314567f04){#F4}

Per cent area deviated from normal distribution {#s3-3}
-----------------------------------------------

Similar to parafoveal capillary density results, per cent area deviated from normal distribution also showed significant differences in the entire image and four quadrants among study groups. Post hoc pairwise comparisons after non-parametric Kruskal-Wallis tests showed that per cent yellow area and per cent red area measured in the entire image and four quadrants were significantly higher in the NP-SCR and P-SCR groups compared with the control group ([table 2](#T2){ref-type="table"}). No statistical significant difference between the NP-SCR and P-SCR was observed in all tested ROIs.

In horizontal asymmetry analysis, the largest absolute per cent yellow area difference was found in the P-SCR group (12.53%±11.52%), followed by the NP-SCR group (9.68%±15.01%) and the control group (2.04%±3.09%). The same trend was also found in vertical asymmetry analysis with the largest absolute per cent yellow area difference found in the P-SCR group (12.84%±10.25%), followed by the NP-SCR group (6.53%±8.62%) and the control group (2.48%±2.12%) ([figure 4C, D](#F4){ref-type="fig"}). However, only the NP-SCR and P-SCR groups showed significant difference in horizontal asymmetry where per cent yellow area in the temporal quadrant was higher than that of the nasal quadrant (p=0.048 and p=0.004, Wilcoxon signed-rank tests). A similar trend was found in the per cent red area horizontal asymmetry where only the P-SCR group showed significantly higher per cent red area at the temporal quadrant than that of the nasal quadrant (p=0.004, Wilcoxon signed-rank test) ([figure 4E, F](#F4){ref-type="fig"}).

Area under the receiver operating characteristic {#s3-4}
------------------------------------------------

The results of the AUROC curve analyses for FAZ metrics, parafoveal capillary density measurements and per cent area deviated from normal distribution are shown in [table 3](#T3){ref-type="table"}. Unlike FAZ area and perimeter, which showed relatively poor diagnostic capability, FAZ acircularity index demonstrated good diagnostic capability of 0.82 AUROC when differentiating between eyes with and without SCR. Parafoveal capillary density and per cent area deviated from normal distribution of the entire OCT-A image also showed good diagnostic capability of 0.84--0.87 AUROC.

###### 

Area under the receiver operating characteristic (AUROC) curve analyses of the FAZ metrics, parafoveal capillary density and per cent area deviated from normal distribution in differentiating eyes without SCR (control) and eyes with SCR (NP-SCR and P-SCR)

  Measurements                   AUROC (95% CI)        
  ------------------------------ --------------------- ---------------------
  FAZ                            Area                  0.58 (0.43 to 0.73)
  Perimeter                      0.69 (0.57 to 0.82)   
  Acircularity index             0.82 (0.72 to 0.92)   
  Parafoveal capillary density   Entire image          0.87 (0.78 to 0.96)
  Temporal                       0.86 (0.77 to 0.95)   
  Nasal                          0.85 (0.76 to 0.94)   
  Superior                       0.85 (0.76 to 0.94)   
  Inferior                       0.83 (0.72 to 0.94)   
  Per cent yellow area           Entire image          0.85 (0.75 to 0.94)
  Temporal                       0.86 (0.76 to 0.95)   
  Nasal                          0.81 (0.71 to 0.91)   
  Superior                       0.84 (0.74 to 0.94)   
  Inferior                       0.73 (0.61 to 0.85)   
  Per cent red area              Entire image          0.84 (0.75 to 0.94)
  Temporal                       0.82 (0.73 to 0.92)   
  Nasal                          0.83 (0.72 to 0.93)   
  Superior                       0.82 (0.72 to 0.92)   
  Inferior                       0.73 (0.59 to 0.86)   

CI, confidence interval; FAZ, foveal avascular zone; NP-SCR, non-proliferative SCR; P-SCR, proliferative SCR; SCR, sickle cell retinopathy.

Discussion {#s4}
==========

Although sickle cell maculopathy has been well documented in patients with sickle cell disease, the lack of quantitative data describing microvascular changes has limited our understanding of early changes in SCR and the best approach to monitoring progression. In recent attempts to measure FAZ area in patients with SCR, some studies using IV-FA and OCT-A have indicated that FAZ area is enlarged in patients with SCR compared with controls.[@R22] Our findings failed to show any statistically significant difference between the control and SCR groups ([figure 2](#F2){ref-type="fig"}). However, given the substantial variability in FAZ area among controls as well as diseased eyes, this metric alone may be insufficient for discriminating controls and patients with SCR.[@R18] Additionally, the discrepancy from our findings may have been due to difference in sample size, the use of both eyes from the same subject or the lack of age and race-matched controls in the prior studies. In agreement with prior OCT-A studies, however, both NP-SCR and P-SCR groups showed significantly higher FAZ acircularity index due to the increased parafoveal capillary tortuosity at the FAZ border, suggesting that FAZ acircularity index may be a more sensitive metric to discriminate SCR from control ([figure 2](#F2){ref-type="fig"}C).

In this study, we employed a unique quantitative approach which measured parafoveal capillary density only after the removal of larger blood vessels. This was performed in a quadrant-specific manner to investigate whether parafoveal capillary dropout preferentially affects particular areas of the macula in SCR. As expected, parafoveal capillary density was found to be lowest in the P-SCR group, followed by the NP-SCR and control group compared with healthy controls. In comparison of parafoveal capillary density measured at four quadrants, both NP-SCR and P-SCR groups showed significantly lower density compared with the control group in all four quadrants ([figure 3](#F3){ref-type="fig"}). Prior studies have demonstrated that retinal thinning temporal to the fovea is associated with peripheral neovascularisation in SCR.[@R15] Our observation of horizontal asymmetry with lower parafoveal capillary density at the temporal retina than the nasal retina in P-SCR group supports the prior observation that capillary dropout is more prevalent in the temporal retina than the nasal retina ([figure 4A](#F4){ref-type="fig"}). It is worth noting that no vertical asymmetry was observed in both SCR groups ([figure 4B](#F4){ref-type="fig"}).

While measurements of parafoveal capillary density using OCT-A have become more common in the literature, the clinical significance of these measurements remains unclear given the lack of comparison to normative values. This study is the first to analyse parafoveal capillary density data in a deviation map comparing SCR to age and race-matched controls. Our normative-based deviation mapping method specifically depicts areas with parafoveal capillary density below 1% (red) and 5% (yellow)of the normal distribution, highlighting areas which are most likely to be abnormal ([figure 5](#F5){ref-type="fig"}, right column). [Figure 5](#F5){ref-type="fig"} shows that while parafoveal capillary density decreases (middle column), total area below 5% and 1% of normal distribution increases with increasing SCR severity (right column). Measurements of regions severely deviated from normal distribution appear to be a more sensitive method for detecting horizontal asymmetry in both NP-SCR and P-SCR groups as compared with using parafoveal capillary density alone ([figure 4C, E](#F4){ref-type="fig"}).

![Comparison of parafoveal capillary density and deviation maps in (top row) healthy control, (middle row) NP-SCR and (bottom row) P-SCR. (Left column) Contrast-stretched full vascular slab OCT-A. (Middle column) Parafoveal capillary density maps with non-capillary blood vessels indicated in white due to the exclusion from density computation. (Right column) Corresponding deviation maps. Parafoveal capillary density below 5% and 1% of the normative database is indicated in yellow and red, respectively. While parafoveal capillary density decreases, total area below 5% and 1% of normal distribution increases with increasing SCR severity. The temporal aspect of the parafovea is to the left in all images. NP-SCR, non-proliferative sickle cell retinopathy; OCT-A, optical coherence tomography angiography; P-SCR, proliferative sickle cell retinopathy.](bjophthalmol-2019-314567f05){#F5}

Notably, our findings did not show statistical significant differences between the NP-SCR and P-SCR groups for any comparisons of FAZ metrics or parafoveal capillary density measurements. We attribute this to the random sampling of the tested eye from the control and SCR groups. To avoid interocular correlation, only one eye was selected randomly from each participant when both eyes were available. However, prior studies have observed that significant interocular asymmetry of FAZ metrics in healthy controls and disease severity in SCR may exist within the same individual.[@R7] Interocular asymmetry together with the random sampling may have reduced the ability to detect statistical significant difference between the NP-SCR and P-SCR groups due to higher data variability. Additional studies evaluating the degree of interocular asymmetry in eyes with SCR might prove useful for determining the more representative eye to grade the extent of disease.

There were a number of limitations to be noted in this study. First, the relatively small sample size restricted our ability to substratify patients with sickle cell according to the Goldberg classification of five different stages of retinopathy. Second, there may have been some artefactual effect on capillary recording due to the reported reduced blood flow velocity in patients with sickle cell disease.[@R31] Some non-perfused capillaries in the patients with SCR may have been the result of blood flow velocities below the detection threshold of the OCT-A system rather than due to non-perfusion. This may have led to an overestimation of FAZ metrics and parafoveal capillary dropout. Third, individual axial length was not obtained for the correction of ocular magnification, reducing the accuracy of the FAZ metrics and parafoveal capillary density measurements.[@R17] Finally, a full vascular slab containing both superficial and deep microvascular networks was used for measurement of parafoveal capillary density. While this approach has been successful in reducing artefactual non-perfusion in patients with macular oedema due to poor OCT layer segmentation in diabetes or vein occlusion, it does not take advantage of OCT-A's ability to measure superficial and deep vascular layers individually. Since sickle cell maculopathy does not take the form of cystic oedema which displaces retinal layers on OCT scans, modifying the method in future studies to look at individual capillary layers might enhance the sensitivity of the technique for this disease.

In summary, our customised OCT-A image processing analysis highlights significant quantitative alterations in perfusion density mapping in a qualitative display, with minimal obscuration in OCT-A image detail. Regardless of the retinopathy stage, FAZ acircularity index appeared higher in patients with SCR when compared with controls. Our findings confirmed the observation of horizontal asymmetry with lower parafoveal capillary density in the temporal retina associated with the presence of neovascularisation in eyes with SCR. The application of normative-based parafoveal capillary density deviation mapping in patients with SCR shows promise for immediate qualitative and quantitative assessments of SCR, which may prove useful for clinical management.
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